Renu Gupta - Corbus Pharmaceuticals Independent Director
| CRBP Stock | USD 35.64 1.39 4.06% |
Director
Dr. Renu Gupta, M.D., is an Independent Director of the Company.. Dr. Gupta became one of our directors in June 2014 since 2014.
| Age | 59 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
| Address | 500 River Ridge Drive, Norwood, MA, United States, 02062 |
| Phone | 617 963 0100 |
| Web | https://www.corbuspharma.com |
Corbus Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.5957) % which means that it has lost $0.5957 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.4198) %, meaning that it created substantial loss on money invested by shareholders. Corbus Pharmaceuticals' management efficiency ratios could be used to measure how well Corbus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Corbus Pharmaceuticals' Return On Capital Employed is relatively stable compared to the past year. As of 05/01/2024, Return On Equity is likely to grow to 6.78, while Return On Tangible Assets are likely to drop (1.66). As of 05/01/2024, Liabilities And Stockholders Equity is likely to grow to about 50.5 M, while Total Current Liabilities is likely to drop slightly above 16.9 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| JeanFranois Formela | Spero Therapeutics | 61 | |
| Svetlana Lucas | aTyr Pharma | N/A | |
| Patrick Vink | Spero Therapeutics | 54 | |
| Isaac Blech | X4 Pharmaceuticals | N/A | |
| Richard Jones | Mereo BioPharma Group | 50 | |
| Richard Spivey | Adverum Biotechnologies | 67 | |
| Murray Stewart | X4 Pharmaceuticals | 57 | |
| Thomas Woiwode | Adverum Biotechnologies | 45 | |
| Deepa Pakianathan | Mereo BioPharma Group | 53 | |
| John Scarlett | CytomX Therapeutics | 67 | |
| Peter Bains | Mereo BioPharma Group | 61 | |
| William Ryan | AN2 Therapeutics | 71 | |
| Mark Lupher | Adverum Biotechnologies | N/A | |
| Vikas Goyal | Spero Therapeutics | 37 | |
| Richard Levy | Kodiak Sciences | 60 | |
| Rekha Hemrajani | Adverum Biotechnologies | 48 | |
| Cynthia Smith | Spero Therapeutics | 49 | |
| Timothy Shannon | CytomX Therapeutics | 56 | |
| Frank Thomas | Spero Therapeutics | 47 | |
| Jeffrey Hatfield | aTyr Pharma | 59 | |
| Mark Auerbach | Assembly Biosciences | 78 | |
Management Performance
| Return On Equity | -3.42 | ||||
| Return On Asset | -0.6 |
Corbus Pharmaceuticals Leadership Team
Elected by the shareholders, the Corbus Pharmaceuticals' board of directors comprises two types of representatives: Corbus Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Corbus. The board's role is to monitor Corbus Pharmaceuticals' management team and ensure that shareholders' interests are well served. Corbus Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Corbus Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MA, Chief Officer | ||
| Ted Jenkins, Senior Director, Investor Relations and Communications | ||
| Mark Tepper, Co-Founder and President and Chief Scientific Officer | ||
| Sean Moran, CFO | ||
| Craig Millian, Chief Commercial Officer | ||
| CPA MBA, Chief Officer | ||
| Lindsey Smith, Head Advocacy | ||
| Scott Constantine, Director Operations | ||
| John Jenkins, Director | ||
| Craig MBA, Chief Officer | ||
| Robert Discordia, Vice President Pharmaceutical Development & Manufacturing | ||
| Alan Holmer, Independent Director | ||
| Christina Bertsch, Head Resources | ||
| Renu Gupta, Independent Director | ||
| Avery Catlin, Independent Director | ||
| David Hochman, Director | ||
| Sergei Atamas, Executive Director - Research | ||
| Barbara White, Chief Medical Officer | ||
| Rachelle Jacques, Director | ||
| Rachael Brake, Chief Officer | ||
| Yuval Cohen, CEO and Director | ||
| Paris Panayiotopoulos, Director |
Corbus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Corbus Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.42 | ||||
| Return On Asset | -0.6 | ||||
| Current Valuation | 373.95 M | ||||
| Shares Outstanding | 10.51 M | ||||
| Shares Owned By Insiders | 0.69 % | ||||
| Shares Owned By Institutions | 59.59 % | ||||
| Number Of Shares Shorted | 623.06 K | ||||
| Price To Earning | (8.87) X | ||||
| Price To Book | 1,491 X | ||||
| Price To Sales | 163.32 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Corbus Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Corbus Pharmaceuticals' short interest history, or implied volatility extrapolated from Corbus Pharmaceuticals options trading.
Pair Trading with Corbus Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Corbus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corbus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Corbus Stock
| 0.68 | SBFMW | Sunshine Biopharma | PairCorr |
| 0.58 | ETON | Eton Pharmaceuticals Financial Report 9th of May 2024 | PairCorr |
| 0.57 | DVAX | Dynavax Technologies Financial Report 7th of May 2024 | PairCorr |
| 0.49 | EVOK | Evoke Pharma | PairCorr |
The ability to find closely correlated positions to Corbus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Corbus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Corbus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Corbus Pharmaceuticals Holding to buy it.
The correlation of Corbus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Corbus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Corbus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Corbus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corbus Pharmaceuticals Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Corbus Pharmaceuticals information on this page should be used as a complementary analysis to other Corbus Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Complementary Tools for Corbus Stock analysis
When running Corbus Pharmaceuticals' price analysis, check to measure Corbus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corbus Pharmaceuticals is operating at the current time. Most of Corbus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corbus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corbus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corbus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |
Is Corbus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Corbus Pharmaceuticals. If investors know Corbus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Corbus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (10.31) | Quarterly Revenue Growth (1.00) | Return On Assets (0.60) | Return On Equity (3.42) |
The market value of Corbus Pharmaceuticals is measured differently than its book value, which is the value of Corbus that is recorded on the company's balance sheet. Investors also form their own opinion of Corbus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Corbus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Corbus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Corbus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Corbus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Corbus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Corbus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.